Suzetrigine
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Acute Pain
Conditions
Acute Pain
Trial Timeline
Mar 21, 2025 → Nov 7, 2025
NCT ID
NCT06887972About Suzetrigine
Suzetrigine is a approved stage product being developed by Vertex Pharmaceuticals for Acute Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT06887972. Target conditions include Acute Pain.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07463430 | Approved | Recruiting |
| NCT07378865 | Phase 1 | Recruiting |
| NCT06887959 | Approved | Completed |
| NCT06887972 | Approved | Completed |
| NCT06696443 | Phase 3 | Active |
| NCT05661734 | Phase 3 | Completed |
Competing Products
20 competing products in Acute Pain